The estimated Net Worth of Shoshana Shendelman is at least $43.1 million dollars as of 5 August 2024. shoshana Shendelman owns over 777,014 units of Applied Therapeutics stock worth over $24,439,271 and over the last 6 years he sold APLT stock worth over $7,027,233. In addition, he makes $11,590,000 as Chairman of the Board, President, Chief Executive Officer et Founder at Applied Therapeutics.
Sign up
shoshana Shendelman APLT stock SEC Form 4 insiders trading
shoshana has made over 14 trades of the Applied Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 777,014 units of APLT stock worth $4,708,705 on 5 August 2024.
The largest trade he's ever made was selling 777,014 units of Applied Therapeutics stock on 5 August 2024 worth over $4,708,705. On average, shoshana trades about 82,012 units every 87 days since 2019. As of 5 August 2024 he still owns at least 4,690,839 units of Applied Therapeutics stock.
You can see the complete history of shoshana Shendelman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
shoshana Shendelman biography
Dr. Shoshana Shendelman Ph.D. serves as Chairman of the Board, President, Chief Executive Officer, Founder of the Company. Dr. Shendelman founded Clearpoint Strategy Group, a boutique strategic advisory firm in NYC, where she currently serves as a Senior Advisor. Dr. Shendelman has directed products through early and late stage development, from conceptual design to product launch for clients including top 10 pharmaceutical companies, biotech start-ups, and VC firms. She received her doctorate from Columbia University in Cellular, Molecular, and Biophysical Studies (CMBS), where her graduate work focused on neuronal stem cell differentiation and molecular mechanisms of Parkinson’s disease.
What is the salary of shoshana Shendelman?
As the Chairman of the Board, President, Chief Executive Officer et Founder of Applied Therapeutics, the total compensation of shoshana Shendelman at Applied Therapeutics is $11,590,000. There are no executives at Applied Therapeutics getting paid more.
How old is shoshana Shendelman?
shoshana Shendelman is 41, he's been the Chairman of the Board, President, Chief Executive Officer et Founder of Applied Therapeutics since 2016. There are 11 older and no younger executives at Applied Therapeutics. The oldest executive at Applied Therapeutics, Inc. is Jay Skyler, 73, who is the Independent Director.
What's shoshana Shendelman's mailing address?
Shoshana's mailing address filed with the SEC is C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY, 10017.
Insiders trading at Applied Therapeutics
Over the last 5 years, insiders at Applied Therapeutics have traded over $14,309,660 worth of Applied Therapeutics stock and bought 5,072,897 units worth $17,896,654 . The most active insiders traders include Real Estate Equities, Inc.A..., Joel S Marcus et Shoshana Shendelman. On average, Applied Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $573,736. The most recent stock trade was executed by Leslie D. Funtleyder on 22 August 2024, trading 13,530 units of APLT stock currently worth $78,880.
What does Applied Therapeutics do?
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
What does Applied Therapeutics's logo look like?
Complete history of shoshana Shendelman stock trades at Applied Therapeutics
Applied Therapeutics executives and stock owners
Applied Therapeutics executives and other stock owners filed with the SEC include:
-
shoshana Shendelman,
Chairman of the Board, President, Chief Executive Officer, Founder -
Riccardo Perfetti,
Chief Medical Officer -
Mark Vignola,
Chief Financial Officer -
Dr. Shoshana Shendelman Ph.D.,
Chair of the Board of Directors, Founder, Pres, CEO & Sec. -
Dr. Riccardo Perfetti,
Chief Medical Officer -
Leslie Funtleyder,
Independent Director -
Dr. Charles Silberstein M.D., CFA,
CFO & Head of Bus. Devel. -
Teena Lerner,
Lead Independent Director -
Joel Marcus,
Independent Director -
Stacy Kanter,
Independent Director -
Jay Skyler,
Independent Director -
Maeve Conneighton,
IR Contact Officer -
Adam Hansard,
Chief Commercial Officer -
Chids Mahadevan,
VP of Fin. & Chief Accounting Officer -
Real Estate Equities, Inc.A...,
-
Constantine Chinoporos,
See Remarks -
Charles Silberstein,
Chief Financial Officer -
Adam Hansard,
Chief Commercial Officer -
Corwin Dale Hooks,
Chief Commercial Officer -
Steven A. Ortega,
Principal Accounting Officer -
Chids Mahadevan,
See Remarks